PATENT CLAIM ANALYSIS

Application Number: 16080529
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-01
Patent Classification: ["514", "252180"]

Abstract:
Imatinib can be used in the treatment of stroke in a new dosage regime, where Imatinib is administered to the patient at a dose of 650 mg/day or higher for at least 3 consecutive days, and preferably administered in a starting dose of 1000 mg/day or higher on day 1, and at a dose in the interval of 650 mg/day to 1000 mg/day on the subsequent days. A method for the treatment of stroke, a pharmaceutical composition and a kit of parts is/are also disclosed.

Claim (Index 31):
The method according to  claim 30 , wherein Imatinib is administered orally or intravenously.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 96.0
- Lexical Diversity: 1.85714
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15859075', '13189413', '14440001', '10206854', '13510560']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7321789518033094
- 35 USC 102 Novelty (BERT): 0.5144430562004996
- Combined Prediction Score: 0.7104053622430284
- Mean Citation Score: 213.16172000000003
- Max Citation Score: 237.532
- Similarity Product: 152.38964672541618

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test